bioAffinity TechnologiesBIAF
Market Cap: $17.8M
About: bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Employees: 75
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
78% more capital invested
Capital invested by funds: $484K [Q1] → $863K (+$379K) [Q2]
21% more funds holding
Funds holding: 14 [Q1] → 17 (+3) [Q2]
1.33% more ownership
Funds ownership: 2.09% [Q1] → 3.43% (+1.33%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Anthony Vendetti 42% 1-year accuracy 5 / 12 met price target | 355%upside $6 | Buy Initiated | 23 Jul 2024 |